Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program

Drug and Alcohol Dependence

Volumn 52, Issue 3, 1998, Pages 193-200

  Torrens, Marta ^a   Castillo, Claudio ^a   San, Lluís ^a   Del Moral, Enrique ^a   González, María L ^b   De La Torre, Rafael ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Cocaine use; Heroin use; Methadone maintenance; Opioid withdrawal symptoms; Plasma EDDP concentrations; Plasma methadone concentrations; Treatment compliance

Indexed keywords

2 ETHYLIDIENE 1,5 DIMETHYL 3,5 DIPHENYLPYRROLIDINE; ANTIINFLAMMATORY AGENT; ANTIMIGRAINE AGENT; BENZODIAZEPINE DERIVATIVE; COCAINE; DIAMORPHINE; DIGESTIVE TRACT AGENT; DRUG METABOLITE; ILLICIT DRUG; METHADONE; OPIATE; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; MIDDLE AGED; NEUROLOGIC EXAMINATION; SENSITIVITY AND SPECIFICITY; SPAIN; SUBSTANCE ABUSE DETECTION; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT REFUSAL;

EID: 0032211799     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(98)00096-9     Document Type: Article

References (34)

1. Abdul-Quader A.S., Friedman S.R., Des Jarlais D.C., Marmor M.M., Maslansky R., Bartelme S. Methadone maintenance and behavior by intravenous drug users that can transmit HIV. Contemp. Drug Probl. 14:1987;425-433.
2. Ball J.C., Lange W.R., Myers C.P., Friedman S.R. Reducing the risk of AIDS through methadone maintenance treatment. J. Health Soc. Behav. 29:1988;214-226.
3. Bell J., Seres B., Bowron P., Lewis J., Batey R. The use of the serum methadone levels in patients receiving methadone maintenance. Clin. Pharmacol. Ther. 43:1988;623-629.
4. Bell J., Bowron P., Lewis J., Batey R. Serum levels of methadone in maintenance clients who persist in illicit drug use. Br. J. Addict. 85:1990;1599-1602.
5. Borg L., Ho A., Peters J.E., Kreek M.J. Availability of reliable serum methadone determination for management of symptomatic patients. J. Addict. Dis. 14:1995;83-96.
6. Charuvastra, C., Gudeman, D.M., Wilkins, J., Ling, W. 1997. Cimetidine may decrease opiate withdrawal symptoms in methadone patients (abstract). In: Harris L.S., (Ed.), Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting. The College on Problems of Drug Dependence, NIDA Research Monograph 174, Department of Health and Human Services, National Institutes of Health, Rockville, MD, pp. 136.
7. Chitasombat P., Willenbring M.L., Maddux T., Severeide N. Reliability of methadone plasma levels in methadone maintenance. Am. J. Addict. 4:1995;351-355.
8. Cobb, M.N., Desai, J., Brown, L.S., Zannikos, P., Trapnell, C., Rainey P.M. 1997. The effect of fluconazole on the clinical pharmacokinetics of methadone (abstract). In: Harris L.S., (Ed.), Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting. The College on Problems of Drug Dependence, NIDA Research Monograph 174, Department of Health and Human Services, National Institutes of Health, Rockville, MD, pp. 137.
9. De Vos J.W., Geerlings P.J., Van den Brink W., Ufkes J.G.R., Van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in twenty opiate addicts. Eur. J. Clin. Pharmacol. 48:1995;361-366.
10. Dole V.P. Foreword. Ball J.C., Ross A. The Effectiveness of Methadone Maintenance Treatment. 1991;VII-VIII Springer, New York.
11. Farrell M., Neelman J., Gossop M., Griffiths P., Bunning E., Finch E., Strang J. Drug Prevention. A Review of The Legislation and Delivery of Methadone in 12 Member States of the European Union. 1996;ECSC-EC-EAEC, Brussels.
12. Gossop M. The development of a short opiate withdrawal scale (SOWS). Addict. Behav. 1990:1990;487-490.
13. Hiltunen A.J., Lafolie P., Martel J. et al. Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients. Psychopharmacology. 118:1995;122-126.
14. Holmstrand J., Anggard E., Gunne L.M. Methadone maintenance: plasma levels and therapeutic outcome. Clin. Pharmacol. Ther. 23:1978;175-180.
15. Horns W.H., Rado M., Goldstein A. Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride. Clin. Pharmacol. Ther. 17:1975;636-649.
16. Kreek M.J. Plasma and urine levels of methadone. NY State J. Med. 73:1973;2773-2777.
17. Kreek M.J. Metabolic interactions between opiates and alcoho. Ann. NY Acad. Sci. 362:1981;36-49.
18. Kreek M.J., Garfield J.W., Gutjahr C.L., Giusti L.M. Rifampicin-induced methadone withdrawal. New Engl. J. Med. 294:1976;1104-1106.
19. Loimer N., Schmid R. The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depend. 30:1992;241-246.
20. Novick D.M., Joseph H., Croxson T.S. et al. Absence of antibody to human inmunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch. Int. Med. 150:1990;97-99.
21. Plummer J.L., Gourlay G.K., Cherry D.A., Cousins M.J. Estimation of methadone clearance: application in the management of cancer pain. Pain. 33:1988;313-322.
22. Schall U., Pries E., Katta T., Klöppel A., Gastpar M Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone. Addict. Biol. 1:1996;105-113.
23. Schoenbaum E.E., Hartel D., Selwyn P.A. et al. Risk factors for Human Inmunodeficiency Virus Infection in intravenous drug users. New Engl. J. Med. 321:1989;874-879.
24. Schuster C.R. The National Institute on Drug Abuse and methadone maintenance treatment. J. Psychoact. Drug. 23:1991;111-112.
25. Sorkin E.M., Ogawa G.S. Cimetidina potentiation of narcotic action. Drug Intell. Clin. Pharm. 17:1983;60-61.
26. Tennant F., Shanon J. Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations. J. Addict. Dis. 14:1995;67-74.
27. Tennant F.S. Jr, Rawson R.A., Cohen A., Tarver A., Clabough D. Methadone plasma levels and persistent drug abuse in high dose maintenance patients. Subst. Alcohol Actions Misuse. 4:1983;369-374.
28. Tong T.G., Pond S.M., Kreek M.J., Jaffery N.F., Benowitz N.L. Phenytoin-induced methadone withdrawal. Ann. Int. Med. 94:1981;349-351.
29. Torrens M., Castillo C., Pérez-Blanco V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 45:1996;55-59.
30. Torrens M., San L., Martínez A., Castillo C., Domingo-Salvany A., Alonso J. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction. 92:1997;707-716.
31. Wolff K., Hay A.W.M. Plasma methadone monitoring with methadone maintenance treatment. Drug Alcohol Depend. 36:1994;69-71.
32. Wolff K., Hay A., Raistrick D. Measuring compliance in methadone maintenance patients: use of a pharmacological indicator to 'estimate' methadone plasma levels. Clin. Pharmacol. Ther. 50:1991;199-207.
33. Wolff K., Sanderson M., Hay A.W.M., Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin. Chem. 37:1991;205-209.
34. Wolff K., Hay A.W.M., Vail A, Harrison K., Raistrick D. Non-prescribed drug use during methadone treatment by clinic- and community-based patients. Addiction. 91:1996;1699-1704.